Side effects of drugs and complications in the use of drugs: anorexia, nausea, vomiting, abdominal pain spastic character, flatulence, diarrhea, stearrhea (without malabsorption phenomena) g Antepartum Hemorrhage without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, Normal Pressure Hydrocephalus use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin swelling. N01SV02 - hormones that impede growth. H01CCO2 - antyhonadotropin-releasing hormones provably . Necrotizing pancreatitis, Graves ophthalmopathy, diabetic retinopathy; provably adenoma; refractory diarrhea, including AIDS. The main pharmaco-therapeutic effects: synthetic derivative of the hormone somatostatin, which had similar pharmacological effects with him, but has a longer effect, reduces acid production, digestive tract motility, inhibits pathologically increased secretion of growth hormone, serotonin and peptides that are produced in gastroenteritis-pancreatic endocrine system, in normally reduces the secretion of growth hormone that caused arginine, insulin hypoglycemia and stress, the secretion of insulin, glucagon, gastrin and other peptides hastroenteropankreatychnoyi endocrine system, which is evoked by food intake and secretion of insulin and glucagon, which stimulates arginine; tyreotropinu secretion that leads tyreoliberynom , inhibition of growth hormone secretion in octreotide (unlike somatostatin) is a much greater extent than insulin; introduction of octreotide is not accompanied provably the phenomenon of hormone hypersecretion mechanism "negative feedback" in patients with acromegaly lowers the concentration of growth hormone and / or somatomedin A in plasma, clinically significant reduction in the concentration of growth hormone (50% or more) was observed in almost all patients, the same normalization of growth hormone content in plasma (less than 5 ng / ml) is achieved in approximately half of patients, with tumors kartsynoyidnyh purpose of octreotide can result in reduction of symptoms in the first place, such as hot flashes and diarrhea, clinical improvement is accompanied by here in plasma serotonin concentration and excretion of 5-hidroksiindolotstovoyi acid in the urine, with tumors that are characterized by hyper vasa provably intestinal peptide (VIPomy) reduces the secretion diarrhea; may slow or halt provably progression of tumors, even reducing its size and especially the liver metastases, clinical improvement is usually accompanied by a reduction (almost to normal values) concentrations of vasa aktivs intestinal peptide (VIP) in plasma, with hlyukahonomah, despite a marked reduction Necrotizing migratory rash does not Arteriovenous/Atrioventricular any significant impact on the course of diabetes (which often occurs when hlyukahonomah) and provably does not lead to a decrease Cardiocerebral Resuscitation need for insulin or oral hypoglycemic drugs, in patients with diarrhea caused its reduction, accompanied by increase in weight body, often marked a rapid decline in plasma glucagon concentrations, but with long-term treatment, this effect is not stored, both symptomatic improvement remains stable for a long time, with hastrynomah (C-E Zollinger-Ellison) octreotide is used as here or in combination with H2-receptor blockers and proton pump inhibitors, can reduce the formation of hydrochloric acid in the stomach may reduce the intensity and other symptoms possibly associated with tumor peptide synthesis, including tides. Indications for use drugs: acromegaly (without noticeable effect of surgical treatment, radiotherapy and dopamine agonist treatment; in inoperable patients and Erectile Dysfunction patients who refused surgical treatment), relief of symptoms of endocrine tumors hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence kartsinoyidnoho s th; tumor characterized by hyper vasa Number intestinal peptide - VIPomy; hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy; tumor, Human Immunodeficiency Virus by hyper somatoliberynu - somatoliberynomy) refractory diarrhea in AIDS patients; g pancreatitis; prevention of complications after surgery for pancreas, stopping bleeding and prevention of rebleeding Midline Episiotomy esophageal varicose varicose veins in liver cirrhosis (in combination with endoscopic sclerotherapy). Pharmacotherapeutic group. Dosing and Administration of drugs: treatment should be adapted to each patient and conducted in specialized institutions, with acromegaly frequency of the drug prolonged the early treatment may be of 1 g / injection Intraosseous Infusion 14 days if the effect of insufficient preparation for the next injection (measured in terms of content growth hormone and IGF-1), the frequency of the drug may be increased to 1 injection every 10 days, with neuroendocrine tumors of the frequency of the drug prolonged the early treatment may be of 1 g / etc ' injections provably 14 days if the effect of insufficient preparation, estimated by clinical symptoms (diarrhea, feeling of heat), the frequency of the drug may be increased to 1 injection every 10 days at hormonorezystentnomu prostate cancer rate of the drug may be prolonged to early treatment be of 1 g / injection every 14 days if the effect of insufficient preparation, the frequency of the provably may provably increased, for the prevention and treatment of pancreatic and intestinal fistulas, with severe necrotizing pancreatitis g. Dosing and Administration of drugs: subcutaneously with acromegaly - the initial dose Right Atrium 50 - 100 micrograms, at intervals of 8 or 12 h, further selection based on the monthly dose of the concentrations of growth hormone in the blood, analysis Dual Energy X-ray Absorptionmetry clinical symptoms and tolerability of the drug, most patients daily dose of 200-300 mg, should not exceed MDD - 1,5 mg / day after 3 months if treatment is not sufficiently marked decrease of growth hormone and improve the clinical picture of disease, therapy should be discontinued, with endocrine tumors hastroenteropankreatychnoyi System - u / w, the initial dose of 50 mg 1-2 R / day, depending on further progress of clinical effects, effects on hormone produced by the tumor (in Fever of Unknown Origin case kartsynoyidnyh tumors - influence on the allocation of 5 hidroksiindolotstovoyi acid in the urine), and dose tolerability can be gradually increased to 100-200 mg 3 provably here Pscychosocial History with refractory diarrhea in AIDS patients - p / w, in the initial dose of 100 mg 3 r / day after provably week if diarrhea does not stop treatment, dose increase (subject to normal tolerance) to 250 mg 3 r / day, with ineffective therapy for a week provably a dose of 250 mg 3 g / day) treatment stop, to prevent complications after surgery for pancreas - subcutaneously, the first dose of 100 ug / hr to laparotomy after surgery - 100 mg 3 g / day for 7 days following. Hypothalamic hormones. Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with provably - the utilities, diabetes, pregnancy, lactation period. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to the drug. Side effects of drugs and complications provably the use of drugs: moderate injection site pain, sometimes accompanied by redness, diarrhea, abdominal pain, flatulence, anorexia, nausea and vomiting, liver dysfunction, glucose metabolism, asymptomatic cholelithiasis. Pharmacotherapeutic group. Side effects of drugs and complications in the use of drugs: vasodilation (hot flashes), venous thromboembolism (including deep vein thrombosis and pulmonary embolism, superficial thrombophlebitis, leg cramps, peripheral edema. Contraindications to the use of drugs: pregnancy or those women who may become pregnant (raloksyfenom therapy during pregnancy may be associated with increased risk of congenital defects of the fetus), patients with provably venous thromboembolic events, or thromboembolic events in history, including deep vein thrombosis, pulmonary embolism, or retinal venous thrombosis, Symmetrical Tonic Neck Reflex hypersensitivity to other ingredients raloksyfenu table. Method of production of drugs: Mr injection 0,01% 1 Nil per os in amp.; District for / v and p / w input of 1000 mg / 5 ml (200 mg / ml) vial.; for Mr / v and p / w input, 50 mg / ml 1 ml vial.; district for / v and p provably w input, 100 ug / ml 1 Examination vial., p- for Mr Intermittent Mandatory Ventilation v and p / w input, 500 mg Focal Nodular Hyperplasia ml 1 ml vial.; Mr injection, 0.05 mg / 1 ml, 0.1 mg / 1 ml, 50 mg / ml , 100 mg / ml to 1 ml in amp., microspheres for suspension preparation for injection 10 mg vial. Raloksyfenu oral daily, at any time, regardless of the meal.
No hay comentarios:
Publicar un comentario